Table 2.

In vivo response to chemotherapy, distribution of types of event and of survival status of children with T-ALL according to genetic subgroups



Total population studied, n

Subgroup

All HOX11L2-negative, n

HOX11L2-positive, n
HOX11-high, n
SIL-TAL, n
Other, n*
Total, N (%)   127 (100)   34 (100)   9 (100)   15 (100)   69 (100)   117 (100)  
Response to prephase       
    Died before evaluation   1 (0.8)   0 (0)   0 (0)   1 (6.7)   0 (0)   1 (0.9)  
    Less than 1000 blasts/μL   79 (62.2)   24 (70.6)   9 (100)   7 (46.7)   39 (56.5)   67 (62.6)  
    At least 1000 blasts/μL   47 (37.0)   10 (29.4)   0 (0)   7 (46.7)   30 (43.5)   39 (36.4)  
MRD       
    ND   59 (46.5)   15 (44.1)   4 (44.4)   8 (53.3)   32 (46.4)   55 (51.4)  
    Absence of marker   12 (9.4)   1 (2.9)   1 (11.1)   0 (0.0)   10 (14.5)   11 (10.3)  
    Less than 10-2  46 [82.1]   13 [72.2]   4 [100]   7 [100]   22 [81.5]   35 [85.4]  
    At least 10-2  10 [17.9]   5 [27.8]   0 [0]   0 [0]   5 [18.5]   6 [14.6]  
Type of event       
    No event (ie, in CCR)   94 (74.0)   25 (73.5)   8 (88.9)   12 (80.0)   49 (71.0)   25 (73.5)  
    No CR   4 (3.1)   0 (0)   0 (0)   1 (6.7)   3 (4.3)   5 (4.7)  
    BM only   12 (9.4)   4 (11.8)   0 (0)   2 (13.3)   6 (8.7)   8 (7.5)  
    CNS only   3 (2.4)   0 (0)   0 (0)   0 (0)   3 (4.3)   7 (6.5)  
    Other isolated relapse   1 (0.8)   0 (0)   0 (0)   0 (0)   1 (1.4)   1 (0.9)  
    Combined   9 (7.1)   4 (11.8)   1 (11.1)   0 (0)   4 (5.8)   5 (4.7)  
    Death in CR   4 (3.1)   1 (2.9)   0 (0)   0 (0)   3 (4.3)   3 (2.8)  
Survival status       
    Alive   99 (78.0)   27 (79.4)   9 (100)   14 (93.3)   49 (71.0)   82 (76.6)  
    Dead
 
28 (22.0)
 
7 (20.6)
 
0 (0)
 
1 (6.7)
 
20 (29.0)
 
25 (23.4)
 


Total population studied, n

Subgroup

All HOX11L2-negative, n

HOX11L2-positive, n
HOX11-high, n
SIL-TAL, n
Other, n*
Total, N (%)   127 (100)   34 (100)   9 (100)   15 (100)   69 (100)   117 (100)  
Response to prephase       
    Died before evaluation   1 (0.8)   0 (0)   0 (0)   1 (6.7)   0 (0)   1 (0.9)  
    Less than 1000 blasts/μL   79 (62.2)   24 (70.6)   9 (100)   7 (46.7)   39 (56.5)   67 (62.6)  
    At least 1000 blasts/μL   47 (37.0)   10 (29.4)   0 (0)   7 (46.7)   30 (43.5)   39 (36.4)  
MRD       
    ND   59 (46.5)   15 (44.1)   4 (44.4)   8 (53.3)   32 (46.4)   55 (51.4)  
    Absence of marker   12 (9.4)   1 (2.9)   1 (11.1)   0 (0.0)   10 (14.5)   11 (10.3)  
    Less than 10-2  46 [82.1]   13 [72.2]   4 [100]   7 [100]   22 [81.5]   35 [85.4]  
    At least 10-2  10 [17.9]   5 [27.8]   0 [0]   0 [0]   5 [18.5]   6 [14.6]  
Type of event       
    No event (ie, in CCR)   94 (74.0)   25 (73.5)   8 (88.9)   12 (80.0)   49 (71.0)   25 (73.5)  
    No CR   4 (3.1)   0 (0)   0 (0)   1 (6.7)   3 (4.3)   5 (4.7)  
    BM only   12 (9.4)   4 (11.8)   0 (0)   2 (13.3)   6 (8.7)   8 (7.5)  
    CNS only   3 (2.4)   0 (0)   0 (0)   0 (0)   3 (4.3)   7 (6.5)  
    Other isolated relapse   1 (0.8)   0 (0)   0 (0)   0 (0)   1 (1.4)   1 (0.9)  
    Combined   9 (7.1)   4 (11.8)   1 (11.1)   0 (0)   4 (5.8)   5 (4.7)  
    Death in CR   4 (3.1)   1 (2.9)   0 (0)   0 (0)   3 (4.3)   3 (2.8)  
Survival status       
    Alive   99 (78.0)   27 (79.4)   9 (100)   14 (93.3)   49 (71.0)   82 (76.6)  
    Dead
 
28 (22.0)
 
7 (20.6)
 
0 (0)
 
1 (6.7)
 
20 (29.0)
 
25 (23.4)
 

Numbers in parentheses and brackets are percentages. CCR indicates continuous complete remission; BM, bone marrow relapse; CNS, central nervous system relapse.

*

Negative for 3 genetic markers.

This group included 107 patients: 9 patients with HOX11-high, 15 patients positive for SIL-TAL, 69 patients with other, and 14 additional patients who tested negative for HOX11L2 and not tested for HOX11 and SIL-TAL status.

Percentages between [] were calculated taking into account only documented cases.

or Create an Account

Close Modal
Close Modal